Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 73, Issue 5, 2012, Pages 617-624

  Kane, John M ^a   Sanchez, Raymond ^b   Perry, Pamela P ^b   Jin, Na ^b   Johnson, Brian R ^b   Forbes, Robert A ^b   McQuade, Robert D ^b   Carson, William H ^b   Fleischhacker, W Wolfgang ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PLACEBO;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; FEMALE; HAZARD RATIO; HUMAN; INJECTION SITE PAIN; INSOMNIA; LOG RANK TEST; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84861837563     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07530     Document Type: Article

References (32)

1. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):996-1008. doi:10.1016/j.pnpbp.206.03.031 PubMed (Pubitemid 43949430)
2. Byerly MJ, Thompson A, Carmody T, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv. 2007;58(6):844-847. doi:10.176/api.ps.58.6.84 PubMed (Pubitemid 46985178)
3. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542-1550. doi:10.408/JCP.v67n108 PubMed (Pubitemid 44787436)
4. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699. doi:10.176/api.ajp.161.4. 692 PubMed (Pubitemid 38445514)
5. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453-460. doi:10.408/JCP.v67n0317 PubMed
6. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423-424. doi:10.102/pds.837 PubMed (Pubitemid 36903380)
7. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260-267. doi:10.1/j.160-047. 206.0982.x PubMed (Pubitemid 46425751)
8. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):9-14. PubMed (Pubitemid 43837696)
9. Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat. 2010;6(6):261-267. doi:10.2147/NDT.S3072 PubMed
10. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389. doi:10.124/jpet.102.03175 PubMed (Pubitemid 34680462)
11. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411. doi:10.1038/sj.np.130203 PubMed (Pubitemid 41070874)
12. Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007;190(3):373-382. doi:10.107/s0213-06-0621-y PubMed (Pubitemid 46155646)
13. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-140. doi:10.1016/S014-29(02)01532-7 PubMed (Pubitemid 34626163)
14. Pigott TA, Carson WH, Saha AR, et al Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056. doi:10.408/JCP.v64n0910 PubMed (Pubitemid 37158250)
15. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65(6):510-517. doi:10.1016/j.biopsych.208. 07.03 PubMed
16. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66(2):183-194; quiz 147, 273-184. PubMed
17. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44(2):179-187. doi:10.17/0912703261901 PubMed (Pubitemid 38114317)
18. Fleischhacker WW, Kane JM, Sanchez R, et al. A pharmacokinetic study of once-monthly aripiprazole extended-release injectable suspension (ARI-ERIS) in adult patients with schizophrenia. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 14-16, 2011; Honolulu, Hawaii.
19. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
20. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: US Department of Health Services; 1976.
21. Lindenmayer JP, Czobor P, Alphs LD, et al. InterSePT Study Group. The InterSePT Scale for Suicidal Thinking: reliability and validity. Schizophr Res. 2003;63(1-2):161-170. doi:10.1016/S0920-964(02)035-3 PubMed (Pubitemid 36934486)
22. Guy W. Abnormal Involuntary Movement Scale (AIMS). US Department of Health Education and Welfare ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:534-537.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(s212):11-19. doi:10.1/j.160-047.1970.tb0206. x PubMed
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed (Pubitemid 19154942)
25. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68(suppl 1):20-27. PubMed
26. Stroup T, McEvoy J, Ring K, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry. 2011; 168(9):947-956. PubMed
27. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. doi:10.1016/j.schres.209.10.026 PubMed
28. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92. doi:10.1016/j.schres. 2010.1.020 PubMed
29. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609. doi:10.176/api.ajp.201.108124 PubMed
30. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851. doi:10.1056/NEJMoa105987 PubMed
31. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377. PubMed
32. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007;191(2):131-139. doi:10.192/bjp.bp.105.017020 PubMed (Pubitemid 47204533)